A new medical condition, possibly linked to mRNA COVID-19 vaccines, has been identified by scientists at Yale University. Dubbed Post-Vaccine Syndrome (PVS), this condition includes a range of long-lasting symptoms that appear months or even years after vaccination.
According to preliminary findings, individuals with PVS experience symptoms such as severe fatigue, brain fog, dizziness, tinnitus, and exercise intolerance. The study, which analyzed blood samples from 42 patients with PVS and 22 vaccinated individuals without symptoms, found notable immune system imbalances. Among the changes were low levels of CD4+ T cells and an increase in CD8+ T cells producing TNF-alpha, a marker of inflammation.
Surprisingly, traces of the COVID-19 spike protein were still detectable in the bloodstream of some PVS patients — long after vaccination. However, this was not the case for all participants, indicating that more research is needed to understand the full picture.
The researchers also noted signs of Epstein-Barr virus (EBV) reactivation, a condition that can trigger flu-like symptoms and neurological complications. EBV is a common virus that often remains dormant in the body, but can reactivate under immune stress, including possibly after vaccination.
The study, led by Dr. Akiko Iwasaki and Dr. Harlan Krumholz, is still in early stages and has not yet been peer-reviewed. Nonetheless, the findings offer a potential explanation for persistent health issues reported by a minority of vaccinated individuals and may lead to diagnostic tools or treatment approaches in the future.
To strengthen their analysis, the team also included data from 134 healthy vaccinated individuals and 134 patients suffering from long COVID, due to the clinical similarities. Both groups showed some overlap in immune responses and virus reactivation.
Meanwhile, earlier data from the U.S. Vaccine Adverse Event Reporting System (VAERS) has shown a notable increase in myocarditis cases following mRNA vaccinations. According to 2021 reports, the incidence was 223 times higher than historical averages across all vaccines over the past three decades.
Yale researchers emphasized that while the results are compelling, they are not conclusive. The next steps include larger studies to determine how common PVS might be and which populations could be at risk.
The identification of Post-Vaccine Syndrome marks an important moment in ongoing COVID-19 research. While the mRNA vaccines have saved millions of lives, this new data suggests the need for ongoing monitoring of long-term effects. It is crucial to strike a balance between public health confidence and a commitment to scientific transparency. As the Yale team continues its research, healthcare providers and policy-makers will need to adapt and respond with care, evidence, and caution.